CARE1 is focused on pragmatic clinical trials, it aims to improve the first-line treatment for patients with metastatic kidney cancer by implementing a routine biomarker, leveraging a unique academic network in Europe.
Focused on pragmatic clinical trials, CARE1 is an European project aiming to improve the first-line treatment for patients with metastatic kidney cancer by implementing a routine biomarker, leveraging a unique academic network in Europe.
See moreCARE1 was designed to determine the optimal combination for patients using a routine implementable biomarker. CARE1 will establish a large-scale platform to define the best standard of treatment based on a routine biomarker to enhance treatment efficacy. In the long term, a data collection effort, including the creation of a pathological and blood biobank, will be conducted on a European scale.
See moreThis project also aims to innovate healthcare, patient care and research by exploring the use of AI in diagnostics and clinical research, and the use of digital tools for patient care.
See moreTo view more, visit our Blog page
Such a crystal clear, thoughtful approach to doublets from @AlbigesL as front line for metastatic #kidneycancer! Doublets are now established standard in trials AND the need for biomarkers for future patient/tx selection. Kudos for the new #CARE1 trial underway in EU! #ASCO23...
"« We are pleased to announce the launch of #CARE1 Project, which officially started on May 1st, 2023. The project was submitted under the Call HORIZON-MISS-2022-CANCER-01-03, focused on pragmatic clinical trials to optimize treatments for patients with refractory cancers. ...
📢 Launch of the pragmatic CARE-1 clinical trial coordinated by Pr @AlbigesL @GustaveRoussy. A key step in the future of kidney cancer care #CARE1 #ClinicalResearch #HealthCareInnovation @HorizonEU...
For further questions, including partnership opportunities, please contact using our contact form.